Drugs / PLOZALIZUMAB
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02723006 | Jun 2016 → May 2018 | melanoma | Millennium Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT02426021 | Apr → Nov 2015 | — | Takeda | Withdrawn | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02388971 | Apr 2016 | atherosclerotic cardiovascular disease | Takeda | Withdrawn | No outcome recorded |
| Phase 2 | NCT02410499 | May → Nov 2015 | diabetic kidney disease | Takeda | Withdrawn | No outcome recorded |
| Phase 2 | NCT01015560 | Mar 2010 → Dec 2012 | cancer of unknown primary site, metastatic malignant neoplasm | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT01199640 | May 2005 → Jul 2007 | multiple sclerosis | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00715169 Comparator | Aug 2005 → Apr 2006 | atherosclerosis | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLOZALIZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707228 ↗ |
| Known as | HU-1D9 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707228 ↗ |
| Known as | MLN1202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02410499 ↗ |
| Known as | TAK-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02723006 ↗ |
| Action | Inhibit | “CCR2 antagonism” NCT02388971 ↗ |
| Modality | Monoclonal antibody | “anti-CCR2 monoclonal antibody MLN1202” NCT01015560 ↗ |
| Route | Intravenous | “administered via IV infusion” NCT00715169 ↗ |
| Target | CCR2 | “anti-CCR2 monoclonal antibody MLN1202” NCT01015560 ↗ |